What it is
GHK is a three amino acid peptide, glycyl-L-histidyl-L-lysine. GHK-Cu is that peptide bound to a copper ion. They are different substances and the literature conflates them constantly. In cosmetic labelling the copper-free peptide is Tripeptide-1 and the complex is Copper Tripeptide-1, and the two are routinely treated as interchangeable.
The complex is roughly 16 percent copper by mass. That number matters later, because it is the difference between reading GHK-Cu as a peptide and reading it as a copper delivery vehicle, and the literature has never settled which it is.
GHK was found in human plasma in the 1970s and published as GHL for its first decade, which is why a search for GHK misses the foundational papers. Its drug name is prezatide, and the copper acetate form was developed as a wound-healing drug, Iamin, by ProCyte in the 1990s. That programme never reached approval.
One detail from the early work sits awkwardly beside how it is marketed now. GHK was originally characterised as a growth factor for hepatoma cells, its discoverer describing effects across cell types ranging from growth stimulation to outright toxicity.
How it works
No receptor for GHK or GHK-Cu has been identified. Every pathway proposed for it is downstream, and the proximal binding event is unknown apart from two single-group claims, to SIRT1 and peroxiredoxin 6.
What has actually been measured
GHK binds copper about as tightly as albumin and can strip it from albumin transport sites (Lau 1981). In fibroblast culture it raises collagen and glycosaminoglycan synthesis, peaking around one nanomolar (Maquart 1988). In rat wound chambers it increases matrix accumulation and collagen messenger RNA where an inactive control tripeptide does not (Maquart 1993).
Is the peptide necessary, or is it carrying copper?
This is the central unresolved question and the evidence contradicts itself in both directions.
Pointing toward copper: the MMP-2 stimulation attributed to GHK-Cu was reproduced by copper ions alone and not by the peptide. In a rabbit corneal model, GHK, ceruloplasmin, its fragments and heparin all induced vessel growth, and only when copper-bound. And the permeation study cited everywhere as proof GHK-Cu penetrates skin measured copper, not intact peptide (Hostynek 2010).
Pointing the other way: one study found copper-free GHK reproduced the effects of the copper complex in keratinocytes. That result would settle a great deal if it held, and in fourteen years nobody has followed it up.
The flagship mechanism points the wrong way
GHK-Cu is widely described as working through TGF-beta activation. The primary data mostly says the opposite. One 2012 paper reports a TGF-beta activation signature. Against it: the foundational rat wound study found no increase in TGF-beta messenger RNA, and studies in 2007, 2014 and 2023 all found the copper complex decreased TGF-beta 1. The direction of the mechanism most often cited for this molecule is contested, and most primary measurements point down.
Research evidence
Human evidence: three controlled trials, two of them negative
The trial is Bishop 1992 in the Journal of Vascular Surgery. Prospective, randomised, evaluator-blinded, three arms, 86 evaluable patients with chronic venous stasis ulcers, comparing 0.4 percent topical tripeptide-copper cream against silver sulfadiazine against an inert vehicle. The copper cream was indistinguishable from placebo and silver sulfadiazine beat both. It is the largest and most rigorous human trial of GHK-Cu ever published, a clean null, and effectively absent from the marketing literature and from the review series that built this compound reputation.
The second, Miller 2006, tested a topical regimen with and without GHK-Cu after CO2 laser resurfacing in thirteen completers. No difference in erythema resolution, no improvement in wrinkles or skin quality on objective evaluation. The only positive was patient-reported satisfaction on a questionnaire.
The third is not really a GHK-Cu trial. Kapoor and Shome 2018 injected a six-component scalp formulation, one component being copper tripeptide-1, open-label, single-arm, no control and no vehicle group. Hair measures improved. Nothing in that can be assigned to the copper peptide, and the authors own the clinic and the formulation. It remains the only published human study in which GHK-Cu was injected.
Where the positive human claims come from
The claim that GHK-Cu creams tighten skin, reduce wrinkles and increase skin density appears in every review and in almost all consumer writing. Trace the reference list of the most-cited review and the entire human basis is four items.
- A one-page abstract from the 2002 American Academy of Dermatology meeting, 71 women, 12-week facial cream. Never peer-reviewed, not in PubMed, no methods, no data tables, no statistics.
- A second one-page abstract from the same 2002 meeting, 41 women, eye cream. Same status.
- A 1998 self-described pilot in a journal that no longer exists and was never PubMed-indexed, reporting percentages improved with no stated denominator.
- A 2005 book chapter, which is not a primary research report.
Two of those four share authors who were then scientific-affairs staff at the manufacturer of a copper-peptide line. The review series propagating the claims lists its authors at the research department of a company selling copper-peptide skincare, while declaring no external funding and no conflict of interest. A 2023 result reported as a randomised controlled trial in 21 women, showing a 28 percent rise in subdermal echogenic density, exists only as a press release.
Stated plainly: no positive result for GHK-Cu comes from an independent, peer-reviewed, controlled human trial. The two peer-reviewed controlled trials are null. The positive human material is industry-originated grey literature.
Registered trials
One interventional efficacy trial has ever been registered, recruiting from February 2026: randomised, double-blind, vehicle-controlled, 60 healthy volunteers, two punch wounds each, topical gel for 14 days, endpoint time to re-epithelialisation, one site in Shenzhen. No results posted, and its own description concedes the rationale is preclinical literature.
A second, not yet recruiting, will test whether a wearable patch marketed on a GHK-Cu premise actually raises blood levels of it. It excludes people with Wilson disease, the only registered acknowledgement in this field that copper loading is a plausible hazard.
There are none at all for diabetic foot ulcer, venous leg ulcer, pressure ulcer, burns, any hair or cosmetic endpoint, any lung condition, any cancer, any cognitive or musculoskeletal condition, or for injectable GHK-Cu by any route.
Preclinical evidence
The animal and cell literature is substantial, including an independent lung programme from Chinese respiratory groups across emphysema, fibrosis, silicosis, acute lung injury and asthma, all by intraperitoneal injection in mice.
Two results run against the grain. A 1995 guinea-pig study found slower skin reorganisation and delayed fibroblast activation. And the closest thing to a musculoskeletal study, a rat ACL model with intra-articular injection, found reduced laxity at six weeks but nothing at twelve, and no difference in ultimate load, gait or histology at any point. The effects did not last once treatment stopped.
Claims that trace to a different molecule or to no experiment
Three citations in this literature do not support the claim attached to them.
- The hair growth paper. The study cited everywhere as evidence GHK-Cu grows hair tested AHK-Cu, a different peptide with a different CAS number. Its title says tripeptide-copper complex, which reads as GHK-Cu. It used molar concentrations in follicle culture and described no topical formulation, so the 0.1 to 0.3 percent figures cited to it appear nowhere in it. The only genuine GHK-Cu hair data is a two-page 1991 meeting proceeding in mice, first-authored from the company developing the product.
- The colon cancer claim. The paper cited for GHK suppressing metastasis genes queried a gene-expression database and found GHK computationally capable of reversing a signature. No GHK touched any cell or patient. A database prediction reported as an experiment.
- The COPD and radiation claims. Same pattern twice. The COPD signature reversal is a database prediction plus cultured fibroblasts; restoring vitality in radiation patients is cell culture from donor explants. No patient was treated in either.
The most repeated fact about this molecule has no published source
Nearly every article, product page and review states that plasma GHK is about 200 nanograms per millilitre at age 20 and falls to 80 by age 60. Following the citation leads to one reference: an unpublished 1973 doctoral thesis by the man who discovered the molecule. Never peer reviewed, no sample size, no cohort description, no assay validation, no error bars, not in PubMed, not independently retrievable.
The peer-reviewed human measurements that do exist do not reproduce that curve. They show something different: plasma GHK is lower in people with COPD and in asthma than in age-matched controls. Association findings in tiny samples, and the most solid human data in this field.
The concentration problem
Topical figures split into two clusters that do not overlap. The dominant one is 1 to 3 percent by weight, a minority cluster 0.05 to 1 percent. They differ by up to sixty-fold, both presented as standard, because no dose-ranging study exists to arbitrate.
Against that, the Cosmetic Ingredient Review panel surveyed actual industry use and found Tripeptide-1 at 0.00002 to 0.001 percent. The circulating figures are three to five orders of magnitude higher, and the panel safety clearance is explicitly bounded to present practices of use and concentration, which is the 0.001 percent end.
The cell literature makes this harder rather than easier. The fibroblast dose-response is biphasic: synthesis peaks around one to ten nanomolar and returns toward control above that. A related copper tripeptide stimulates below ten micromolar and inhibits above it. More is not better in any primary measurement of this molecule, and the circulating figures sit far above the window where anything was observed.
Safety
There is no human pharmacokinetic study of GHK or GHK-Cu by any route. No half-life, no clearance, no bioavailability figure. The circulating half-life numbers, usually 30 minutes free and four to six hours albumin-bound, are unattributed, and the papers cited beside them contain no half-life value.
The only pharmacokinetic data of any kind is a single intravenous dose in rats from 1997, whose headline finding is rapid degradation to the dipeptide His-Lys. Whether administered GHK-Cu survives intact in plasma, or hands its copper straight to albumin and histidine as the binding chemistry predicts, is unknown, and that one unknown sits under every systemic dosing rationale.
The copper is the part worth thinking hardest about. At 16 percent copper by mass, the circulated 1.7 mg per day is about 270 micrograms of elemental copper injected daily, against an oral adult intake of 900. That understates it, because copper homeostasis is regulated at the intestine and injection bypasses that. Nobody has measured serum copper, ceruloplasmin or liver copper in anyone injecting it.
On toxicology the Cosmetic Ingredient Review panel stated its gaps directly: data on carcinogenicity were not found in the published literature, nor on reproductive and developmental toxicity, and no penetration data were identified. Separately, no acute or repeat-dose study, no no-effect level and no lethal dose figure appears in PubMed.
FDA position on the injectable form, from its Category 2 page: compounded injectable GHK-Cu may pose risk for immunogenicity through aggregation and peptide-related impurities, with limited human data to inform safety.
One more unexamined question. Closely related copper tripeptides act as peroxidase mimics and generate reactive oxygen species with ascorbate and oxygen, in one case irreversibly inactivating an enzyme. Whether GHK-Cu does the same in the body is untested. The review series for this molecule recommends pairing it with vitamin C, the exact combination that drives that chemistry.
Regulatory status
GHK-Cu is not an approved drug for any indication, in any form, by any route, anywhere, and there is no pending application. Prezatide copper acetate is a registered development entity from the ProCyte programme that never reached approval.
In cosmetics the picture is different and frequently misdescribed. Copper Tripeptide-1 sits in the European Commission ingredient database as skin conditioning, in no restriction annex, so there is no EU maximum. The Cosmetic Ingredient Review panel concluded it is safe in present practices of use and concentration, but that panel is industry-funded and self-regulatory, and FDA does not pre-approve cosmetic ingredients. Claims that GHK-Cu is FDA approved are wrong in both directions.
GHK-Cu is not on the 503A bulk drug substances list. It appears on the Category 2 page among substances nominated but withdrawn, entered for injectable routes, and withdrawal is not a clearance. Compounding under 503A requires a pharmacopoeial monograph, membership of an approved drug, or a place on that list. GHK-Cu meets none of the three and is absent from 503B entirely.
Handling and identity
Two CAS numbers circulate and suppliers use them interchangeably, one for the free peptide and one for the copper complex. A certificate of analysis quoting the free-peptide number for a product sold as GHK-Cu describes a different substance. Whether the powder is the 1:1 complex, the acetate salt, a mixture, or free peptide plus a copper salt is not verifiable from a label.
The peptide holds up in water between pH 4.5 and 7.4 but is cleaved under oxidative stress. Shelf life of reconstituted injectable GHK-Cu has no published source, and neither does copper speciation in bacteriostatic water or what the copper does in a multi-peptide vial alongside BPC-157, TB-500 and KPV. Nobody has published on that last question at all.
The 1980 Nature paper names the molecule glycyl-L-lysine in its own abstract, leaving the histidine out, and that error has propagated into citation databases.